AIM•benzinga•
AIM ImmunoTech Announces Progress In Ampligen Clinical Trials Targeting Pancreatic Cancer And Long-COVID; Upcoming Milestones Over 18 Months Backed By National Cancer Institute, AstraZeneca, And Merck
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 15, 2025 by benzinga